This month Amplia (ASX:ATX) achieved a significant milestone, announcing that the first patient has been recruited into our ACCENT trial for the treatment of early stage, advanced pancreatic cancer.
In partnership with our research collaborators at The Garvan Institute of Medical Research, we have today published a media release titled, ‘Australian-made treatment for pancreatic cancer – clinical trial milestone’. This was shared with selected journalists to support patient recruitment for the trial.
Read today's media release here.
